News

  • 1 December 2016

    Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, was awarded Financing Deal of the Year at last night’s SCRIP awards at the Grosvenor House Hotel, Park Lane, London.

  • 1 December 2016

    Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ASN100 for the prevention of Staphylococcus aureus pneumonia in mechanically ventilated patients who are at high risk for S. aureus pneumonia.

  • 28 November 2016

    TopiVert, a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and eye, announced today that its Investigational New Drug (IND) application for the evaluation of TOP1630 ophthalmic solution as a treatment of patients with dry eye syndrome (DES) has been approved by the US Food and Drug Administration (FDA).

  • 11 November 2016

    Wilson Therapeutics AB (publ), today announced that updated preliminary data from the company’s ongoing Phase 2 clinical trial for WTX101 (bis-choline tetrathiomolybdate; Decuprate®) in Wilson Disease will be presented at the Liver Meeting®, organized by the American Association for the Study of Liver Diseases (AASLD), in Boston, Massachusetts, November 11-15.

  • 9 November 2016

    Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, will present positive data from its Phase I clinical monotherapy trial in uveal melanoma (UM) of its lead product, IMCgp100, an ImmTAC (Immune mobilising monoclonal TCRs Against Cancer). These data demonstrate clear early evidence of monotherapy activity of IMCgp100 in patients with uveal melanoma and strengthens the data announced at ASCO 2016.